Inhibition of cancer stem cell like cells by a synthetic retinoid

Area of Science:

• Oncology
• Drug Discovery
• Cancer Research

Background:

• Developing novel therapeutics to combat malignant tumor growth and metastasis remains a significant challenge.
• Tumor-repopulating cells (TRCs) are a key target due to their resistance to conventional treatments.

Purpose of the Study:

• To investigate the efficacy of a novel synthetic retinoid, WYC-209, against malignant melanoma TRCs.
• To determine the mechanism of action and potential therapeutic applications of WYC-209.

Main Methods:

• WYC-209's effect on murine and human melanoma, lung, ovarian, and breast cancer TRC proliferation was assessed.
• In vivo studies in mice evaluated WYC-209's ability to inhibit melanoma lung metastases.
• Retinoic acid receptor (RAR) antagonists and caspase 3 inhibitors were used to elucidate the drug's mechanism.

Main Results:

• WYC-209 inhibited melanoma TRC proliferation with an IC50 of 0.19 μM and prevented growth resumption post-treatment.
• The compound significantly reduced lung metastases by 87.5% in mice without apparent toxicity.
• Mechanism studies indicated WYC-209 targets RAR and induces apoptosis via the caspase 3 pathway.

Conclusions:

• WYC-209 demonstrates potent anti-proliferative and anti-metastatic activity against drug-resistant cancer TRCs.
• The novel retinoid shows significant therapeutic promise for treating malignant melanoma and potentially other cancers.
• WYC-209 offers a potential new treatment strategy with high efficacy and low toxicity.